Thyroid Cancer clinical trials in District of Columbia

6 actively recruiting thyroid cancer trials at 1 site across District of Columbia.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.

NCT ID: NCT03093116

Sites in District of Columbia:

Local Institution - 2106 — Washington D.C., District of Columbia
Local Institution - 2110 — Washington D.C., District of Columbia

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Academic/Other

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …

Sponsor: Institut de Recherches Internationales Servier

NCT ID: NCT05786924

Sites in District of Columbia:

Georgetown University Lombardi Cancer Center — Washington D.C., District of Columbia

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research s…

Sponsor: Massachusetts General Hospital

NCT ID: NCT05668962

Sites in District of Columbia:

MedStar Washington Hospital Center — Washington D.C., District of Columbia

View on ClinicalTrials.gov →

Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05334069

Sites in District of Columbia:

MedStar Georgetown University Hospital — Washington D.C., District of Columbia
MedStar Washington Hospital Center — Washington D.C., District of Columbia

View on ClinicalTrials.gov →

NA Recruiting Academic/Other

Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer

The goal of this study is to learn if a decision aid (DA) website helps people with thyroid cancer make informed decisions about radioactive iodine (RAI) treatment. The main questions it aims to answer are: - Does the decision aid help par…

Sponsor: Georgetown University

NCT ID: NCT06980103

Sites in District of Columbia:

Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
MedStar Washington Hospital Center — Washington D.C., District of Columbia

View on ClinicalTrials.gov →

NA Recruiting Academic/Other

Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients

The goal of this clinical trial is to learn if adult patients diagnosed with differentiated thyroid cancer can easily use and benefit from an online tool aimed to provide patients with educational resources and symptom management strategie…

Sponsor: Georgetown University

NCT ID: NCT06853925

Sites in District of Columbia:

Georgetown University — Washington D.C., District of Columbia

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20